Management Team


COLIN STORY
DR – Chief Executive Officer (CEO)

Non-Executive Director of Hox Therapeutics
Co-founder and former CEO of OxSonics
Co-founder and former Non-Executive Director of OrthoSon



SALVATORE CALABRESE
Chief Financial Officer (CFO)

+20 years of experience in the life sciences sector
Former CFO at Gain Therapeutics Inc. (NASDAQ: GANX)
Former CFO at Molmed S.p.A (MI: MLMD)
Former GM & Site Leader at Jazz Pharmaceutical SpA
Former CFO & COO at Gentium SpA (Nasdaq. GENT)



PIETRO BUBBA BELLO
Head of Manufacturing & Operations

Former Site Head, Director of Operations, and Plant Director of Operations and HSE Country Manager at Novartis
Former Site Head and Qualified Person and Head of Quality Control at Advanced Accelerator Applications



JASON SCHENSE
Head of Product Development

Former Chief Technology Officer at Kuros Biosciences AG
Extensive experience in product development in USA & EU



GIANLUCA DE DANIELI MD, MsC
Head of Clinical Development

Former Medical Head, Italy and CEE at Advanced Accelerator Applications
Former Medical Lead, Fabry & Endocrinology Disease at Sanofi Genzyme
Former Medical Manager at Dompé and Medical Advisor at GE Healthcare



BETTY POLIKAR
Head of Clinical Operations

Former Responsible of Start-Up Unit, Clinical Research Center of Excellence at Ospedale Pediatrico Bambino Gesù, Rome
Former Strategic Consultant, Clinical Development and Clinical Operations



GAIA BISACCIONI
Director of RA/QA

Former Quality Site Head at Advanced Accelerator Applications
Former Quality Site Head & Deputy Qualified Person at Advanced Accelerator Applications


Board of Directors


RICCARDO PALMISANO
MD –Chairman

Past President of Assobiotec
Former CEO at MolMed
Former VP and/or GM at Menarini Group, Shire, GSK, Genzyme and Sanofi



COLIN STORY
DR – Chief Executive Officer (CEO)

Non-Executive Director of Hox Therapeutics
Co-founder and former CEO of OxSonics
Co-founder and former Non-Executive Director of OrthoSon



DIANA SARACENI
MS – Designated by Panakès

Co-founder and Managing Partner of Panakes Partners
Former Co-founder and Managing Partner at 360 Capital



CLAUDIO GIULIANO
MS – Designated by Innogest

Founder and CEO of Innogest Capital
Former Chairman of CV Committee at AIFI – the Italian Association of PE and VC
Former Vice President at Carlyle Group



GIOVANNI CERUTTI
MS – Designated by C2 Shareholders

Business Unit Head in Advanced Accelerator Applications, a Novartis Company (AAA)
Former Country Business Manager in GE HealthCare /Amersham



LUCA MELINDO
MS – Designated by C3 Shareholders

+20 years as Financial Executive
Former Senior Investment Manager ad Finde SpA



MICHELIN THERIN
DVM, PhD – Independent Board Member

President of MT2 Consulting
Former President Advanced Therapies at Siemens Healthineers
Former Global Vice President at Medtronic Minimally Invasive Therapies Group


Clinical Advisory Board


Professor JAFAR GOLZARIAN
MD CHAIRMAN – Interventional Radiologist

Univ. of Minnesota Divisional Director IR & Vascular Imaging
Co-founder & President of GEST annual symposium
A KOL and thought leader n interventional radiology in the US



Professor LUIGI SOLBIATI
MD – Interventional Radiologist

Professor of radiology at Huminatas University
Consufant radiologist at Huminatas Research Hospital
Performed the world’s first liver ablation in 1993



Professor ROBERTO IEZZI
MD – Interventional Radiologist

Associate Professor. Department of Radiology Universes Catolica
Director of International Radiology at Policlinico Gemelli Rome



Professor GOVINDARAJAN NARAYANAN
MD – Interventional Radiologist

Chief of IR at Miami Cardiovascular & Miami Cancer Institutes
Course Director of the SPECTRUM IR oncology conference
A KOL and thought leader in interventional radiology in the US



Professor THOMAS VOGL
MD – Interventional Radiologist

Director, Specialist in Radiology, University Hospital Frankfurt




BetaGlue
Technologies SpA


Legal headquarters:

Piazzetta Umberto Giordano, 4
20122 Milano, Italy


info@betaglue.com

VAT number: 06496571214

REA MI-2502397

Paid-in capital: € 784.616


© BetaGlue 2022. All rights reserved.